KRRO · Korro Bio, Inc.

Korro Bio’s Q1 2026 results reflect a strategic pivot toward capital efficiency and program prioritization. The $19.6 million net loss—narrower than the $23.4 million loss in Q1 2025—was driven primarily by a $6.8 million reduction in R&D expenses, largely attributable to winding down KRRO-110-related activities and lower personnel costs, though partially offset by increased investment in KRRO-121. The complete absence of collaboration revenue ($0 vs. $2.6 million) stems directly from the 12-month pause in the Novo Nordisk agreement initiated in November 2025, confirming a deliberate de-emphasis on partnered revenue during this phase. G&A expenses declined modestly to $7.5 million, with lower facilities and IT costs counterbalanced by higher stock-based compensation—a sign of ongoing retention efforts amid pipeline advancement. Critically, the $85 million oversubscribed private placement materially de-risks the near-term operating plan: combined with the $157.1 million cash balance as of March 31, 2026, Korro now expects to fund operations into the second half of 2028. This runway explicitly covers clinical data readouts for both KRRO-121 and the GalNAc-conjugated AATD program—two value inflection points central to investor expectations. Management commentary underscores confidence in the OPERA platform’s scalability, citing >90% in vivo RNA editing in AATD preclinical models and continued chemistry refinements presented at ASGCT 2026. With KRRO-121’s regulatory filing targeted for H2 2026 and a development candidate for AATD expected in Q2 2026, the financial profile supports execution against near-term catalysts without immediate dilution risk.